Significant Agreements (Details)		1 Months Ended	3 Months Ended		9 Months Ended
	Sep. 26, 2022 USD ($) treatment	Sep. 30, 2024 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
BARDA | Emergent
Schedule of Investments
Proceed from the contract amendment		$ 67,400,000	$ 67,400,000		$ 67,400,000
Emergent | TEMBEXA | Base Period
Schedule of Investments
Up-front cash payment	$ 238,000,000
Quantity royalty rate, trigger (treatments) | treatment	1,700,000
Emergent | TEMBEXA | Base Period | Non- United States
Schedule of Investments
Gross profit royalty rate (as a percent)	15.00%
Emergent | TEMBEXA | Base Period | United States
Schedule of Investments
Gross profit royalty rate (as a percent)	20.00%
Emergent | BARDA
Schedule of Investments
Payment to be received upon achievement of milestones		2,700,000	2,700,000		2,700,000
Emergent | BARDA | Base Period
Schedule of Investments
Maximum milestone proceeds upon the exercise of options	$ 124,000,000
SymBio Pharmaceuticals | Scenario, Plan
Schedule of Investments
Deferred revenue	$ 12,500,000
Emergent Biodefense Operations Lansing LLC
Schedule of Investments
Revenue recognized			2,000	$ 11,000	2,000	$ 200,000
Ohara Pharmaceutical Co., Ltd.
Schedule of Investments
License agreement, nonrefundable regulatory milestone payment to be received								$ 2,500,000
License agreement, fixed overhead reimbursement		$ 3,300,000
Ohara Pharmaceutical Co., Ltd. | Scenario, Adjustment
Schedule of Investments
Research and development expenses			$ (500,000)		$ (500,000)
CR Sanjui | Oncoceutics, Inc.
Schedule of Investments
Payment to be received upon achievement of milestones							$ 5,000,000